Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
Fate Therapeutics announced the dosing of the first patient in the RECLAIM-LN Phase 2 potentially registrational trial evaluating FT819 for lupus nephritis, alongside FDA clearance of the IND for its dual-CAR T-cell candidate FT839. Financially, the company reported Q2 revenue of $2.1 million and a narrowed net loss of $(0.25) per share, driven by a reduction in operating expenses.
Key figures
- Revenue
- 2100000
- Drug Name
- FT819
- Guidance
- Operating runway into 2028
- Phase Of Trial
- Phase 2
- Net loss
- 30200000
- Cash burn
- 21000000
- Cash position
- 153800000
- Operating expenses
- 33200000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.